Skip to main content
. Author manuscript; available in PMC: 2021 Jan 22.
Published in final edited form as: Nature. 2020 Jul 22;583(7818):845–851. doi: 10.1038/s41586-020-2513-4

Figure 1: Segregation of STAT5- and ERK-activation in human B-ALL.

Figure 1:

a, Correlation between ERK-pT202/Y204 and STAT5-pY694 levels in B-ALL cells (n=23 independent biological samples; P=0.001, two-tailed t-test; r=−0.657, Pearson r). b, Western blots of patient-derived B-ALL cells (n=8, left), Ph+ B-ALL cells before (n=8, middle) and after ponatinib treatment (n=8, right). c, Single-cell phosphoprotein analysis of patient-derived B-ALL samples (n=3 independent experiments). d, Patient-derived Ph+ B-ALL cells treated with trametinib or ponatinib. Growth inhibition (%) shown (means of 3 independent experiments). For gel source data, see Supplementary Fig. 1.